This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Andrew Kennedy, Ph.D.
Head of Peptides at Achilles Therapeutics UK Limited

Profile

Dr. Andrew Kennedy is the Head of Peptides for Achilles Therapeutics and an expert in peptide synthesis, process development and manufacture. After completing his PhD in Organic Chemistry at the University of Glasgow under the supervision of Professor Graeme Cooke, he then went on to specialize in peptide chemistry with Almac Sciences based in Edinburgh. Dr. Kennedy has held several senior scientist positions over the years in the chemical industry, and also the medical devices field, focusing on verification and validation of novel medical devices and release of products to market. More recently he held the position of Global Product Manager for the Peptides Business of Gyros Protein Technologies, managing their portfolio of peptide synthesizers, reagents and consumables. Currently, Dr Kennedy leads the peptide team at Achilles Therapeutics based in London, specialising in the synthesis of neoantigen peptides.

Agenda Sessions

  • Tides, T-Cells & Therapeutics: How Clonal Neoantigen Peptides Are Used to Develop a Targeted, Autologous Solid Cancer Treatment

    14:30